Heart Tumor Market Research Report—Global Forecast till 2030

Heart Tumor Market Research Report: Information by Tumor Type (Primary Tumors and Secondary Tumors), by Diagnosis & Treatment (Diagnosis & Treatment), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

ID: MRFR/HC/3629-CR | | Region: Global | 137 Pages         

Heart Tumor Market

Heart Tumor Market is anticipated to register at 6.31% CAGR to reach USD 1.36 Billion during the forecast period 2022-2030

Segmentation

By Tumor Type Primary Tumor Secondary Tumor
By Diagnosis & Treatment Diagnosis Treatment

Key Players

  • Tomtec Imaging Systems GmBh
  • Koninklijke Philips N.V.
  • Siemens Healthineers
  • Circle Cardiovascular Imaging Inc.
  • Toshiba Corporation
  • Shimadzu Corporation
  • CardioComm Solutions Inc.
  • Integer Holdings Corporation
  • Pie Medical Imaging
  • HeartSciences
  • 3mensio Medical Imaging
  • eMedica S.L.

Drivers

  • Growing prevalence of cardiac tumors
  • Increasing number of cancer research and funding
Speak to Analyst Request a Free Sample

Heart Tumor Market Overview:


The Heart Tumor Market size is projected to be worth USD 1.36 billion by 2030, registering a CAGR of 6.31% during the forecast period (2022-2030). The market was valued at USD 783.34 million in 2021.


An abnormal growth of heart tissue is referred to as a cardiac tumor, which can be either cancerous (malignant) or non-cancerous. Cardiac Tumor can also be categorized as primary (coming from the heart itself) or secondary. Primary cardiac tumor is extremely uncommon, affecting just around 1 in 3000 people. The majority of initial heart tumor—75%—are benign. Secondary cardiac tumor most frequently develops in people with lung cancer, breast cancer, melanoma, renal cell carcinoma, or lymphoma and are 20–30 times more likely than primary cardiac tumor. The market is driven by factors like the growing prevalence of cardiac tumors, increasing number of cancer research and funding, and the rising number of strategic initiatives. Nevertheless, increasing initiatives by public and private organizations to drive awareness regarding heart tumor is anticipated to create lucrative opportunities for the players operating in the heart tumor market. However, lack of awareness among people, and lack of skilled radiologists could hamper the growth of the heart tumor market.


COVID-19 Analysis


The COVID-19 pandemic had negatively impacted the heart tumor market in the initial phase of the pandemic, causing a reduction in productivity, shutdown/reduced activity in manufacturing plants, and disruption in the supply chain.


However, the COVID-19 pandemic has moderately disrupted the production and revenue of many companies. Most key players have their manufacturing units in different regions which were highly affected by this pandemic due to restriction laid down by the authorities to curb virus transmission. Key companies such as Koninklijke Philips N.V. (Netherlands), Siemens AG (Germany), Hitachi, Ltd. (Japan), GE Healthcare (US) and others are highly dependent on several regional markets for revenue generation, but the pandemic and slowdown globally had negatively affected the company’s growth in these regions in 2020. For instance, the shortage of Iodinated Contrast Media (ICM) due to a General Electric manufacturing shutdown in Shanghai, China owing to COVID-19 lockdown in April 2022, has caused significant effects on radiology practices globally.


Heart Tumor Market Dynamics


Market Drivers



  • Growing prevalence of cardiac tumors

    • The growing prevalence of heart tumors including cardiac sarcoma, arrhythmia, chest pain, stroke, and pericardial effusion is one of the major factors driving the heart tumor market. In addition, the growing incidences of cardiac sarcoma and rising asymptomatic carriers, particularly during the COVID-19 pandemic, have further contributed to the market growth. This is due to the rising chest pain and swelling of the feet, legs, ankles, or belly. It also causes the veins to stand out leading to the growing prevalence of cardiac sarcoma attributable to an increased risk of heart tumor. Moreover, according to the data published by the Centers for Disease Control and Prevention (US) in 2021 stated that 697,000 people in the US died from heart disease in 2020, which is 1 in every 5 deaths. These aforementioned factors have positively contributed to the overall market growth.



  • Increasing number of cancer research and funding

  • Rising number of strategic initiatives


Market Restraints



  • Lack of awareness among people

    • The lack of awareness regarding symptoms, ignorance, and not seeking timely diagnosis and treatment for heart tumors is anticipated to hamper the market growth. The World Health Organization (WHO) in October 2021 stated that 2.2 million people globally suffer from Cardiovascular Diseases (CVDs). However, nearly half of them could have been prevented by receiving proper treatment on time. Moreover, the lack is awareness is more in the developing regions of the world where the people are not conditioned to understand cardiac problems beyond the need. According to a study conducted by National Center for Biotechnology Information (NCBI), around 77.2% of males and 78.2% of females aged above 60–79 is estimated to have cardiac cancer. The study also stated that a significant proportion of the population suffering from cardiac health is not aware of cardiovascular disease. Therefore, a lack of awareness regarding cardiac cancer negatively impacts the growth of the heart tumor market



  • Lack of skilled radiologists


Market Opportunities



  • Increasing Initiatives by public and private organizations to drive awareness regarding heart tumor

    • An increase in the number of initiatives by various public and private organizations to create awareness and educate people regarding cardiac tumors is anticipated to bolster the market growth in the forthcoming year. For instance, in February 2021, European Commission launched its Europe’s Beating Cancer Plan to sets out a new EU approach to cancer prevention, treatment, and survivorship. Furthermore, the initiative is aimed at increasing awareness regarding the risks of tumors and educating the multitude to care for their health, recognize the symptoms, and prompt people at risk and their families to take action

    • Moreover, increasing Initiatives by public and private organizations to drive awareness regarding heart tumor are anticipated to provide lucrative growth opportunities for market players globally.




Value Chain Analysis


The value chain analysis for the heart tumor market comprises four major components that start with the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and ends with post-sales monitoring.


In the research and product development stage, new techniques and research are undertaken to develop new products, and to make the existing products better and unique. In manufacturing stage, the product strategies are ready, and the manufacturing process of the product starts. In distribution & sales, the company's marketing and sales strategies play a crucial role in understanding the characteristics of the industry in which one is competing. Many players sponsor seminars, knowledge sessions, and other activities, including checking for potential interactions and providing advice, each of which is expected to guarantee the end user gets the awareness, full advantage, and value from the products accordingly. Furthermore, in the post-marketing monitoring stage, it begins with a periodic safety update report of the drug or device to be submitted to the FDA after the drug or device comes into the market.


Segment Overview


Tumor Type



  • Primary Tumor


Primary Heart Cardiac (PCT) is a deadly and uncommon condition. Primary tumors are classified into malignant and benign. For instance, according to a SpringerLink article from October 2020, 10% are malignant tumors that are pathologically labelled as sarcomas, and about 90% are benign tumors. Moreover, the major benign tumors that have high chances of becoming malignant are myxomas, rhabdomyoma, and others, including fibromas, lipomas, hemangiomas, papillary fibroelastomas, cystic tumors of the atrioventricular node, and paragangliomas. Soft tissue sarcomas are the common PCTs.



  • Secondary Tumor


The common secondary cardiac tumor is epicardial compared to myocardial and endocardial, and only 10% are symptomatic secondary tumors. For instance, in June 2020, a ScienceDirect article on cardiac tumors reported that SCTs are 20 to 40 times common and frequent than Primary Cardiac Tumors (PCTs). At autopsy, approximately 12% of patients are diagnosed with SCTs, with the majority remaining clinically silent.


By Diagnosis & Treatment



  • Diagnosis


The heart tumor can be diagnosed by CT scans, Magnetic Resonance Imaging (MRI) scans, nuclear imaging, echocardiography, and others. The cardiac CT scan is used to identify narrowed or blocked arteries. Moreover, cardiac MRI provides multiplanar information related to the cardiac masses, including surrounding structures. It is also beneficial due to the appropriate identification of benign and malignant tumors as well as in providing psuedomass information. In addition, other diagnosis methods includes for heart tumor is Electrocardiogram (ECG), electrophysiology tests and cardiac biopsy.



  • Treatment


The treatment segment includes surgery, chemotherapy, radiotherapy, and others. Surgical procedures include surgical excision, transplantation, and catheterization. Additionally, Surgery removes the growth of cancerous tumors or cancerous tumors. For instance, according to the Journal of Cardiothoracic Surgery published in April 2019, it is effective, durable, and safe for primary benign cardiac tumors. A study conducted in the Journal of Cardiothoracic Surgery from 2008 to 2018 showed that 19 men and 31 women were enrolled with left atrium (80.0%), right atrium (16.0%), right ventricle (2.0%), and left ventricle (2.0%) from age 55 to 17.5 years.


Regional Analysis


GLOBAL HEART TUMOR MARKET SHARE (%), BY Region, 2021
GLOBAL HEART TUMOR MARKET SHARE (%), BY Region, 2021
Source: MRFR analysis


The North America held the largest market share of 40.72% based on region and is anticipated to dominate the overall heart tumor market during the forecast period.


North America


The North America comprising the US and Canada— North America held the largest market share in 2021. This is due to factors such as the major use of cardiac biopsies and high prevalence of PCTs in the region. According to a research article published in the International Journal of Surgery (IJS) by Mohamed Rahouma et al, in March 2020, a meta-analysis on cardiac tumors and the utilization of heart transplantation was performed. Primary Malignant Cardiac Tumors (PMCTs) are a minority of Primary Cardiac Tumors (PCTs) and are more prevalent in North America and Europe than in other regions, which is supplementing demand for the heart tumor market


north america HEART TUMOR MARKET SHARE (%), BY country, 2021
north america HEART TUMOR MARKET SHARE (%), BY country, 2021
Source: MRFR analysis


Asia-pacific


Asia-Pacific is anticipated to register the highest CAGR of 8.06% over the forecast period. This is due to factors like presence off several key companies and they are actively investing and expanding through acquisitions, mergers, expansion, and product launches in the region. According to an article published in June 2018 by the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), cardiac rhabdomyoma tumor is the most common cardiac tumor in the fetus in Japan.


Competitive Landscape


The global heart tumor market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency. Market Research Future’s analysis revealed that market players have adopted different strategies and innovative research and development techniques to expand their business and secure their position in the global preclinical heart tumor market. In recent years, strategic movements by major players included approvals, which have been used as market penetration strategies and a means to reduce competition


Moreover, the major players have adopted strategies such as acquisitions, expansion, and collaborations to augment their position in the market. For instance, in April, 2022 Shimadzu Corporation (Japan) launched the Trinias Angiography system to improve medical device visibility. It contains extra customization capabilities that allow for the establishment of a basic, user-friendly workspace that allows for successful operation in a medical setting


List of companies with HQ



  • Koninklijke Philips N.V (The Netherlands)

  • FUJIFILM Corporation (Japan)

  • GE Healthcare (US)

  • Siemens (Germany)

  • Amneal Pharmaceuticals llc (US)

  • Shimadzu Corporation (Japan)

  • TomTec Imaging Systems GmbH (Germany)

  • Toshiba Corporation (Japan)

  • Boston Scientific Corporation (US)

  • Terumo cardiovascular systems corporation (US)


Recent Developments



  • In May 2022, GE Healthcare (US) and Alliance Medical (UK) collaborated to improve patient access to diagnostics and enhance radiology productivity using data analytics and AI.

  • In April 2021, Koninklijke Philips N.V. (Netherlands) received FDA 510(k) clearance for 3D CT image acquisition software. This software will provide interventionalists with CT-like 3D images to support diagnosis, therapy planning, treatment, and follow-up for interventional radiology procedures

  • In November 2021, Siemens Healthineers (Germany) introduced Magnetom Free. Star, is a cost-effective whole-body MRI scanner designed to enable significantly better access to magnetic resonance imaging.


Report Overview


The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.


Study Objectives



  • To provide a comprehensive analysis of the global heart tumor market and its sub-segments, thereby providing a detailed structure of the industry

  • To provide detailed insights into factors driving and restraining the growth of the global heart tumor market

  • To estimate the market size of the heart tumor market where 2018 to 2020 would be the historical period, 2021 shall be the base year, and 2023 to 2030 will be the forecast period for the study

  • To provide strategic profiling of key companies (manufacturers and distributors) present across countries and comprehensively analyze their competitiveness/competitive landscape in this market

  • To provide a value chain analysis for the heart tumor market.


Market Segmentation:


Global Heart Tumor Market, Tumor Type



  • Primary Tumor

  • Secondary Tumor


Global Heart Tumor Market, By Diagnosis & Treatment



  • Diagnosis

    • CT Scan

    • MRI Scan

    • Nuclear Imaging

    • Echocardiography

    • Others



  • Treatment

    • Surgery

    • Chemotherapy

    • Radiotherapy

    • Others




Global Heart Tumor Market, By Region



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America





Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 1.36 Billion
  CAGR   6.31%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2018 to 2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Tumor Type, Diagnosis & Treatment, and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
  Key Vendors   Koninklijke Philips N.V (The Netherlands), FUJIFILM Corporation (Japan), GE Healthcare (US), Siemens (Germany), Amneal Pharmaceuticals llc (US), Shimadzu Corporation (Japan), TomTec Imaging Systems GmbH (Germany), Toshiba Corporation (Japan), Boston Scientific Corporation (US), and Terumo cardiovascular systems corporation (US)
  Key Market Opportunities   â€¢ Increasing initiatives by public and private organizations to drive awareness regarding heart tumor
  Key Market Drivers   â€¢ Growing prevalence of cardiac tumors • Increasing number of cancer research and funding • Rising number of strategic initiatives


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :